— Compensation report — Compensation of the Board of Directors for 2021
Compensation of the Board of Directors for 2021
Note: Mandatory compensation disclosure took effect as per the first day of trading of medmix shares on September 30, 2021. For maximum transparency, medmix opted to disclose compensation paid as of the spin-off date of September 20, 2021.
The following table discloses the compensation paid to the members of the Board of Directors for financial year 2021 while performing services for medmix:
|
thousands of CHF |
|
Cash fees |
|
Restricted share unit (RSU) plan 2) |
|
Social security contributions 3) |
|
Total |
|
Greg Poux-Guillaume, Chairman |
|
42 |
|
79 |
|
12 |
|
133 |
|
Jill Lee |
|
22 |
|
41 |
|
6 |
|
69 |
|
Marco Musetti |
|
22 |
|
41 |
|
4 |
|
67 |
|
Board of Directors 1) |
|
86 |
|
161 |
|
22 |
|
269 |
1) Member of the Board of Directors since September 20, 2021.
2) RSU awards granted in 2021 had a fair value of CHF 43.9167 at grant date. The amount represents the full fair value of grants made in 2021.
3) The amount includes mandatory social security contributions on the cash fees and estimated contributions on the RSU (based on their fair value at grant) paid by the company on behalf of the Board members.
As of December 31, 2021, there were no outstanding loans or credits granted to the members of the Board of Directors, former members of the Board of Directors or related parties. In 2021, no compensation was granted to former members of the Board of Directors or related parties.
Reconciliation between the reported board compensation and the amount approved by the shareholders at EGM
At the EGM 2021, shareholders approved a maximum aggregate compensation amount of kCHF450 for the Board of Directors for the period of office from the 2021 EGM until the 2022 AGM. The table below shows the reconciliation between the compensation that was/will be paid out for the periods of office and the maximum aggregate compensation amounts approved by the shareholders.
|
thousands of CHF |
|
Compensation earned during financial year as reported from the EGM of Sulzer till the end of year (A) |
|
Plus compensation accrued from Jan to AGM of medmix of year following financial year (B) |
|
Total compensation earned for the period from EGM of Sulzer to AGM of medmix (A+B) |
|
Amount approved by shareholders at respective EGM |
|
Ratio between compensation earned for the period from EGM to AGM versus amount approved by shareholders |
|
2021 EGM - 2022 AGM |
|
September 20, 2021 to December 31, 2021 |
|
January 01, 2022 to 2022 AGM |
|
2021 EGM to 2022 AGM |
|
2021 EGM |
|
2022 AGM |
|
Board of Directors total |
|
269 |
|
83 |
|
352 |
|
450 |
|
78.20% |